Market Overview

UPDATE: Morgan Stanley Downgrades Teva Pharmaceutical on Earnings Pressure

Share:
Related TEVA
7 Stocks Which Plummeted Three Days On Increasing Volume
Mike Khouw Sees Unusual Options Activity In Teva Pharmaceutical
Amgen Migraine Drug Likely To Beat Eli Lilly, Alder, Teva To Market (Investor's Business Daily)

In a report published Monday, Morgan Stanley analyst David Risinger downgraded Teva Pharmaceutical (NYSE: TEVA) from Equal-Weight to Underweight, and removed the $40.00 price target.

In the report, Morgan Stanley noted, “Earnings face significant pressure in 2014-2017E when Copaxone, Treanda, and Nuvigil go generic. Copaxone margin pressure offsets cost cuts in our base case. Despite discounted valuation, we believe other stocks in our coverage universe offer a better risk-reward on revenue and growth prospects. Bull/bear cases continue to hinge on Copaxone franchise durability. Brand pipeline success, cost cutting, and external deals could drive upside.”

Teva Pharmaceutical closed on Friday at $38.91.

Latest Ratings for TEVA

DateFirmActionFromTo
Sep 2016OTR GlobalInitiates Coverage onPositive
Sep 2016OppenheimerUpgradesPerformOutperform
Aug 2016Leerink SwannMaintainsOutperform

View More Analyst Ratings for TEVA
View the Latest Analyst Ratings

Posted-In: David Risinger Morgan StanleyAnalyst Color Downgrades Analyst Ratings

 

Related Articles (TEVA)

View Comments and Join the Discussion!